Imunosuppresants Flashcards
Alemtuzumab target use and notes
CD52
CLL, MS
Bevacizumab
Target: VEGF
Use: Colorectal cancer, renal cell carcinoma, non-small cell lung cancer
Cetuximab
EGFR
Stage IV colorectal cancer, head and neck
Rituximab
CD20
B cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP
Tastuzumab
HER2/Neu
Breast cancer, gastric cancer
Adalimumab, certolizumab, golimumab
Soluble TNF-alpha
IBD, rheumatoid arthritis, ankylosis spondylitis, psoriasis
Daclizumab
CD25
Relapsing MS
Eculizumab
Complement protein C5
Paroxysmal nocturnal hemoglobinuria
Natalizumab
Alpha4 interin
MS, crohn disease
Ustekinumab
IL12/IL23
Psoriasis, psoriatic arthritis
Bevacizumab
Antibody against VEGF
Used for solid tumors (colorectal cancer, RCC)
AE: Hemorrhage, blood clots, impaired wound healing
Erlotinib
Mech: EGFR tyrosine kinase inhibitor
Use: Non small cell lung carcinoma
AE: rash
Cetuximab
Use: Anti EGFR
Use: IV colorectal cancer, head and neck
AE: Rash, LFTs, diarrhea
Imatinib
Mech: Tyrosine kinase inhibitor of BCL-ABL and cKIT
Use: CML, GI Stromal tumors
AE: Fluid retention
Rituximab
Monoclonal antibody against CD20
Nonhodgkin lymphoma, CLL, ITP, rheumatoid arthritis
AE: Increased risk of progressive multi focal leukoencephalopathy
Bortezomib, carfilzomib
Mech: Proteasome inhibitors, arrest at G2-M phase
Use: Multiple myeloma, mantle cell lymphoma
AE: Peripheral neuropathy, herpes zoster
Tamoxifen, raloxifene
Mech: Selective estrogen receptor modulator - receptor antagonists in breast and agonists in bone. BLock the binding of estrogen in ER+ cells
Use: Breast cancer treatment and prevention. Raloxefene is used to prevent osteoporosis
Trastuzumab
Mech: Monoclonal antibody against HER2, a tyrosine kinase receptor
Use: Her2 + breast cancer and gastric cancer
AE: Cardiotoxicity “Heartceptin” damages the heart
Vemurafenib
Small molecule inhibitor of BRAF + melanoma V600E mutated BRAF inhibition
Use: Metastatic melanoma
Rasburicase
Recombinant uricase that catalyzes metabolism of uric acid into Allentoin
Prevention and treatment of tumor lysis syndrome
Bosentan
Competitively antagonizes ENdothelin 1 decreasing pulmonary vascular resistance
AE: Hepatotoxic